Status:
NOT_YET_RECRUITING
Impact of Thoracic Duct Ligation on Postoperative Weight Reduction in Obese Patients Receiving Minimally Invasive Lung Surgery: A Clinical Investigation
Lead Sponsor:
Yongxin Zhou
Conditions:
Obese Patients
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This clinical trial aims to investigate whether thoracic duct ligation (TDL) can improve obesity and lipid metabolism. The primary questions it seeks to answer are: Whether thoracic duct ligation can...
Detailed Description
Background: Obesity (BMI≥28 kg/m²) is a global health crisis with limited effective interventions. Emerging evidence suggests that TDL-a routine step in esophagectomy-may reduce body weight and impro...
Eligibility Criteria
Inclusion
- Age \& Gender: Individuals aged 18-75 years, regardless of gender.
- Clinical Profile:Diagnosed with early-stage lung cancer (stage IA1-IB) and obesity (BMI ≥28 kg/m²).
- Scheduled to undergo video-assisted thoracoscopic surgery (VATS) for right-sided lung cancer resection at our institution between October 2024 and October 2026.
- Surgical Eligibility: Approved for surgery following multidisciplinary team (MDT) assessment.
- Treatment Plan: No requirement for adjuvant therapy post-lung resection.
- Preoperative Evaluation:Completed standard preoperative workup, including:
- Chest CT、Brain CT/MRI、Abdominal ultrasound OR PET-CT to rule out distant metastasis.
- Informed Consent: Willing and able to comply with study requirements, with written informed consent provided.
Exclusion
- Concurrent Thoracic Infections: Patients with active intrathoracic infectious diseases (e.g., inflammatory conditions, tuberculosis).
- Refusal of Novel Technique: Patients unwilling to undergo intraoperative thoracic duct ligation.
- Clinically Unstable Comorbidities: Severe, unstable cardiovascular, renal, or respiratory disorders.
- Prior Bariatric Surgery: History of weight-loss surgery (e.g., gastric bypass, sleeve gastrectomy).
- Recent Trial Participation: Enrollment in other clinical trials within 30 days prior to screening.
- Investigator Discretion: Other conditions deemed by the investigator to contraindicate participation.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06995599
Start Date
June 1 2025
End Date
December 31 2027
Last Update
May 29 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.